Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Healthtrust
Chubb
Federal Trade Commission
Citi
Cerilliant
Boehringer Ingelheim
McKesson
Fish and Richardson

Generated: April 19, 2018

DrugPatentWatch Database Preview

BANZEL Drug Profile

« Back to Dashboard

When do Banzel patents expire, and when can generic versions of Banzel launch?

Banzel is a drug marketed by Eisai Inc and is included in two NDAs. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-seven patent family members in thirty-four countries.

The generic ingredient in BANZEL is rufinamide. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rufinamide profile page.
Summary for BANZEL
Drug patent expirations by year for BANZEL
Synonyms for BANZEL
1-(2,6-Difluorobenzyl)-1H-1,2,3-triazol-4-carboxamide
1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4 carboxamide
1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide
1-[(2,6-difluorophenyl)methyl]-4-triazolecarboxamide
1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide
1-[[2,6-bis(fluoranyl)phenyl]methyl]-1,2,3-triazole-4-carboxamide
106308-44-5
1H-1,2,3-Triazole-4-carboxamide, 1-((2,6-difluorophenyl)methyl)-
1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-
308R445
3B1-000291
A801414
AB0017630
AB00918347_06
AB00918347-05
AB1008455
AC-1429
AC1L2V8C
AKOS005145897
AN-598
API0012839
AS-13861
AS07135
Banzel (TN)
Banzel, Rufinamide
BC224496
C10H8F2N4O
CAS-106308-44-5
CCG-222100
Cgp 33101
CGP-33101
CGP33101
CHEBI:134966
CHEMBL1201754
CS-1455
CTK8E9248
D02OBK
D05775
D0MD2L
DB06201
DSSTox_CID_26506
DSSTox_GSID_46506
DSSTox_RID_81675
DTXSID1046506
E 2080
E-2080
E2080
EN300-120881
F0001-2404
FT-0656828
GTPL7470
HE005618
HE293185
HE293186
HMS2232M19
HMS3262O14
HMS3371A06
HMS3651O05
HY-A0042
I06-1425
Inovelon
Inovelon/Banzel
J-001568
J10459
KS-00000YSQ
LP00796
MCULE-6872329028
MFCD00865314
MLS001332513
MLS001332514
MolPort-005-942-441
NCGC00165883-01
NCGC00165883-02
NCGC00165883-03
NCGC00165883-04
NCGC00261481-01
POGQSBRIGCQNEG-UHFFFAOYSA-N
PubChem14896
Q503
R0143
RT-015464
RUF 331
RUF-331
Rufinamide
Rufinamide (Banzel)
Rufinamide (JAN/USAN/INN)
Rufinamide (USAN/INN)
Rufinamide [USAN:INN:BAN]
Rufinamide, >=98% (HPLC), powder
Rufinamide, United States Pharmacopeia (USP) Reference Standard
s1256
SBB070637
SCHEMBL230448
SMR000857122
SR-01000842156
SR-01000842156-4
SYN-111
SYN111
Tox21 112267
Tox21_112267
Tox21_112267_1
Tox21_500796
UNII-WFW942PR79
W-5135
WFW942PR79
Xilep
Z1541638521
ZB000661
ZINC7782

US Patents and Regulatory Information for BANZEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc BANZEL rufinamide SUSPENSION;ORAL 201367-001 Mar 3, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-002 Nov 14, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-001 Nov 14, 2008 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-002 Nov 14, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BANZEL
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 100 mg, 200 mg and 400 mg ➤ Subscribe 2012-11-14
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2014-06-16

Non-Orange Book US Patents for BANZEL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,455,556 Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for BANZEL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB07/041 United Kingdom ➤ Try a Free Trial PRODUCT NAME: CRYSTAL MODIFICATION A OF RUFINAMIDE; REGISTRATION NO/DATE: EU/1/06/378/001 - 015
2007 00037 Denmark ➤ Try a Free Trial PRODUCT NAME: RUFINAMID, KRYSTALMODIFIKATION A
0994863/01 Switzerland ➤ Try a Free Trial PRODUCT NAME: RUFINAMID; REGISTRATION NUMBER/DATE: SWISSMEDIC 58097 06.01.2009
C/GB07/041 United Kingdom ➤ Try a Free Trial PRODUCT NAME: CRYSTAL MODIFICATION A OF RUFINAMIDE; REGISTRATION NO/DATE: EU/1/06/378/001 - 015
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Healthtrust
Citi
Fuji
US Department of Justice
Fish and Richardson
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.